Acquisitions Amorcyte Acquistion (Details) (Amorcyte Acquisition [Member], USD $)	12 Months Ended
	Dec. 31, 2011	Jul. 13, 2011
Amorcyte Acquisition [Member]
Business Acquisition, Contingent Consideration [Line Items]
Profit Loss Since Acquisition	$ 900,000
Stock Converted To Contingent Common Stock Right, Value	673,600
Business Acquisition, Purchase Price Allocation, Goodwill Amount		4,100,000
Earn Out Payments, Percent of Net Sales	10.00%
Earn Out Payments Percentage Sublicensing Fees	30.00%
Earn Out Payment Reduced Percentage	50.00%
Contingent Shares Issued Upon Phase Completion, Shares	1,364,256
Fair Value of Assets Acquired	4,400,000
Business Acquisition, Cost of Acquired Entity, Cash Paid		8,500,000
Equity Issued In Business Combination Fair Value Disclosure	3,700,000
Stock Converted To Common Stock Right Value	940,000
Fair Value of Earn Out Payments	$ 3,100,000
Earnings Per Share Basic And Diluted Since Acquisition	$ 0.01